PRTN3 and graft versus host disease: Compared to GVHD-free patients, patients who developed aGVHD exhibited slightly higher AAT levels on days 0, +14, and +28, yet without reaching statistical significance (Figure 1D); PR3 inhibition was similarly superior on days 0, +7, and +14 (Figure 1E).